Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.40 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | TMPRSS2 | O15393 | 2/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | EP300 | Q09472 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2278277 | 0.96 | HDAC6 (0.44) | HDAC6HDAC8PRMT5NOTUMGSTP1 | |
| SCHEMBL1027650 | 0.90 | HDAC6 (0.47) | HDAC6HDAC8GSTP1GSTM2HDAC3 | |
| SCHEMBL2273673 | 0.89 | HDAC6 (0.61) | HDAC6HDAC8GSTP1GSTM2MCHR1 | |
| SCHEMBL1027131 | 0.88 | HDAC6 (0.45) | HDAC6HDAC8HDAC3HDAC1TMPRSS2 | |
| SCHEMBL2278219 | 0.88 | HDAC6 (0.62) | HDAC6HDAC8GSTP1GSTM2HDAC1 | |
| SCHEMBL1026122 | 0.86 | HDAC6 (0.43) | HDAC6HDAC8GSTP1GSTM2MCHR1 | |
| SCHEMBL1082528 | 0.85 | HDAC6 (0.53) | HDAC6HDAC8ENPP2 | |
| SCHEMBL1028176 | 0.84 | HDAC6 (0.42) | HDAC6HDAC8MCHR1 | |
| SCHEMBL2279957 | 0.84 | NAMPT (0.44) | HDAC6HDAC8 | |
| SCHEMBL2275604 | 0.84 | HDAC6 (0.42) | HDAC6HDAC8PRMT5GSTP1GSTM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575193-B2 | N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds | 4SC AG (DE) | 2013-11-05 | — | — | US | disclosed |
| US-20110201643-A1 | NOVEL N-SUBSTITUTED TETRAHYDROISOQUINOLINE/ISOINDOLINE HYDROXAMIC ACID COMPOUNDS | 4SC AG (DE) | 2011-08-18 | — | — | US | disclosed |
| EP-2100879-A1 | Novel N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds | 4SC AG (DE) | 2009-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201643-A1 | NOVEL N-SUBSTITUTED TETRAHYDROISOQUINOLINE/ISOINDOLINE HYDROXAMIC ACID COMPOUNDS | HDAC1, HDAC3, HDAC4 | HDAC6 7/4885HDAC8 10/4885PRMT5 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.